A novel community-based therapeutic education program for reducing alcohol-related harms and stigma in people with alcohol use disorders: A quasi-experimental study (ETHER study).
France
alcohol use disorder
harm reduction
psychosocial skills
therapeutic patient education
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
07
09
2022
received:
10
06
2022
accepted:
19
12
2022
pubmed:
2
2
2023
medline:
23
3
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Alcohol use disorder (AUD) is associated with a significant disease burden in France, where alcohol use is deeply rooted in culture. However, the treatment gap is large because of several barriers, including stigmatisation and drinkers' apprehension about total abstinence. However, standardised and evidence-based interventions based on controlled-drinking for people with AUD are lacking. We aimed to assess the effectiveness of a novel community-based French therapeutic patient education (TPE) program for people with AUD named Choizitaconso. A before-after non-randomised quasi-experimental study, named ETHER, was designed and implemented with people living with AUD, over a period of 6 months. The primary outcome was percentage change in the number of alcohol-related harms experienced. Secondary outcomes were percentage changes in psycho-social patient-reported and community-validated outcomes. Participants in the intervention group (n = 34) benefited from the 10-week TPE program Choizitaconso, while the comparison group (n = 58) received standard care. The Kruskall-Wallis and chi-squared or Fisher's exact tests were used to compare before-after changes in variables in both groups. Linear regression models were used to test for the effect of study group on each outcome and to test for the effect of alcohol consumption as a confounder. At 6 months, all outcomes but one either remained stable or numerically improved in both groups. Internalised stigma significantly improved in the intervention group (p = 0.026) but not in the comparison group (p = 0.207), with a significant group effect (p = 0.014). This study demonstrates the effectiveness of the Choizitaconso TPE program on community-validated outcomes, especially internalised stigma.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
664-679Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-17-EURE-0020
Organisme : ARS PACA (Agence Régionale de Santé de Provence-Alpes Côte d'Azur)
Organisme : Excellence Initiative of Aix-Marseille University - A*MIDEX
Informations de copyright
© 2023 The Authors. Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.
Références
Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2018;392:1015-35.
The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. 2018;5:987-1012.
Bonaldi C, Hill C. La mortalité attribuable à l'alcool en France en. Bull Epidémiol Hebd. 2015;2019:97-108.
Trias-Llimós S, Bardoutsos A, Janssen F. Future alcohol-attributable mortality in France using a novel generalizable age-period-cohort projection methodology. Alcohol Alcohol. 2021;56:325-33.
World Health Organization. Global status report on alcohol and health 2018 [internet]. Geneva: WHO; 2018. p. 369. Available from: https://apps.who.int/iris/handle/10665/274603
Font H, Roelandt JL, Behal H, Geoffroy PA, Pignon B, Amad A, et al. Prevalence and predictors of no lifetime utilization of mental health treatment among people with mental disorders in France: findings from the mental health in general population (MHGP) survey. Soc Psychiatry Psychiatr Epidemiol. 2018;53:567-76.
Constant A, Sherlaw W, Kovess-Masfety V. Seeking mental health care from private health practitioners among individuals with alcohol dependence/abuse; results from a study in the French general population. Alcohol. 2017;59:1-6.
Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394:781-92.
Probst C, Manthey J, Martinez A, Rehm J. Alcohol use disorder severity and reported reasons not to seek treatment: a cross-sectional study in European primary care practices. Subst Abuse Treat Prev Policy. 2015;10:32.
Costa M, Barré T, Coste M, Yaya I, Berenger C, Tanti M, et al. Screening and care for alcohol use disorder in France: expectations, barriers and levers using a mixed-methods approach. BMC Public Health. 2020;20:358.
Luquiens A, Aubin HJ. Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene. Patient Prefer Adherence. 2014;8:1347-52.
van Amsterdam J, van den Brink W. Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. J Psychopharmacol. 2013;27:987-97.
Henssler J, Müller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression. Addiction. 2021;116:1973-87.
Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol. 2011;46:105-12.
Schomerus G, Schwahn C, Holzinger A, Corrigan PW, Grabe HJ, Carta MG, et al. Evolution of public attitudes about mental illness: a systematic review and meta-analysis. Acta Psychiatr Scand. 2012;125:440-52.
Schomerus G, Matschinger H, Angermeyer MC. Attitudes towards alcohol dependence and affected individuals: persistence of negative stereotypes and illness beliefs between 1990 and 2011. Eur Addict Res. 2014;20:293-9.
Smith SM, Dawson DA, Goldstein RB, Grant BF. Examining perceived alcoholism stigma effect on racial-ethnic disparities in treatment and quality of life among alcoholics. J Stud Alcohol Drugs. 2010;71:231-6.
Sarkar S, Balhara YPS, Kumar S, Saini V, Kamran A, Patil V, et al. Internalized stigma among patients with substance use disorders at a tertiary care center in India. J Ethn Subst Abus. 2019;18:345-58.
Crapanzano KA, Hammarlund R, Ahmad B, Hunsinger N, Kullar R. The association between perceived stigma and substance use disorder treatment outcomes: a review. Subst Abus Rehabil. 2018;10:1-12.
Carrara BS, Ventura CAA. Self-stigma, mentally ill persons and health services: an integrative review of literature. Arch Psychiatr Nurs. 2018;32:317-24.
Lloyd C. The stigmatization of problem drug users: a narrative literature review. Drugs Educ Prev Policy. 2013;20:85-95.
Hammarlund R, Crapanzano K, Luce L, Mulligan L, Ward K. Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders. Subst Abus Rehabil. 2018;9:115-36.
Kulesza M, Ramsey S, Brown R, Larimer M. Stigma among individuals with substance use disorders: does it predict substance use, and does it diminish with treatment? J Addict Behav Ther Rehabil. 2014;3:1000115.
Williams LD, Mackesy-Amiti ME, Latkin C, Boodram B. Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs. Drug Alcohol Depend. 2021;221:108626.
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399:61-116.
Pauly BB, Vallance K, Wettlaufer A, Chow C, Brown R, Evans J, et al. Community managed alcohol programs in Canada: overview of key dimensions and implementation. Drug Alcohol Rev. 2018;37(Suppl 1):S132-9.
Stockwell T, Zhao J, Pauly B, Chow C, Vallance K, Wettlaufer A, et al. Trajectories of alcohol use and related harms for managed alcohol program participants over 12 months compared with local controls: a quasi-experimental study. Alcohol Alcohol. 2021;56:651-9.
Koerkel J. Behavioural self-management with problem drinkers: one-year follow-up of a controlled drinking group treatment approach. Addict Res Theory. 2006;14:35-49.
Favrod-Coune T, Aebischer G, Grondin-Giletti F, Girod I, Simoneau H, Broers B. «Alcochoix+»: controlled drinking within a structured programme - a cohort study in Switzerland. Swiss Med Wkly. 2019;149:w20120.
Thornicroft G, Mehta N, Clement S, Evans-Lacko S, Doherty M, Rose D, et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. Lancet. 2016;387:1123-32.
World Health Organization. Regional Office for Europe. Therapeutic patient education: continuing education programmes for health care providers in the field of prevention of chronic diseases: report of a WHO working group [internet]. Copenhagen: Copenhagen: WHO Regional Office for Europe; 1998 Report No: EUR/ICP/QCPH 01 01 03 Rev.2. Available from: http://apps.who.int/iris/handle/10665/108151
Lagger G, Pataky Z, Golay A. Efficacy of therapeutic patient education in chronic diseases and obesity. Patient Educ Couns. 2010;79:283-6.
Kindelan-Calvo P, Gil-Martínez A, Paris-Alemany A, Pardo-Montero J, Muñoz-García D, Angulo-Díaz-Parreño S, et al. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. Pain Med. 2014;15:1619-36.
Albano MG, Golay A, Andrade VD, Crozet C, d'Ivernois JF. Therapeutic patient education in obesity: analysis of the 2005-2010 literature. Ther Patient Educ. 2012;1:S101-10.
Lian J, McGhee SM, So C, Chau J, Wong CKH, Wong WCW, et al. Long-term cost-effectiveness of a patient empowerment Programme for type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2019;21:73-83.
Guillemot S. Place et apports de l'éducation thérapeutique du patient en addictologie/tabacologie. Rev Mal Respir Actual. 2014;6:248-52.
Antwerpes S, Costa M, Coste M, Bureau M, Maradan G, Cutarella C, et al. Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduct J. 2022;19:2.
Costa M, Barré T, Antwerpes S, Coste M, Bureau M, Ramier C, et al. A community-based therapeutic education programme for people with alcohol use disorder in France: A qualitative study (ETHER). Int J Environ Res Public Health. 2022;19:9228.
Casanova D, Cruz CGD, Hourrier K, Riccobono-Soulier O, Seguin J, Vassas S, et al. Un apport à la réduction des dommages en alcoologie. Alcoologie Addictologie. 2018;40:334-9.
Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: reliability and validity of a theory-based scale for substance-using populations. Drug Alcohol Depend. 2016;162:34-43.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158:1789-95.
Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. International quality of life assessment. J Clin Epidemiol. 1998;51:1171-8.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-70.
Ritz L, Lannuzel C, Boudehent C, Vabret F, Bordas N, Segobin S, et al. Validation of a brief screening tool for alcohol-related neuropsychological impairments. Alcohol Clin Exp Res. 2015;39:2249-60.
Sourial N, Wolfson C, Zhu B, Quail J, Fletcher J, Karunananthan S, et al. Correspondence analysis is a useful tool to uncover the relationships among categorical variables. J Clin Epidemiol. 2010;63:638-46.
Clement S, Schauman O, Graham T, Maggioni F, Evans-Lacko S, Bezborodovs N, et al. What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol Med. 2015;45:11-27.
Rao R, Topiwala A. Alcohol use disorders and the brain. Addiction. 2020;115:1580-9.
Kamaradova D, Latalova K, Prasko J, Kubinek R, Vrbova K, Mainerova B, et al. Connection between self-stigma, adherence to treatment, and discontinuation of medication. Patient Prefer Adherence. 2016;10:1289-98.
Holubova M, Prasko J, Ociskova M, Marackova M, Grambal A, Slepecky M. Self-stigma and quality of life in patients with depressive disorder: a cross-sectional study. Neuropsychiatr Dis Treat. 2016;12:2677-87.
Holubova M, Prasko J, Latalova K, Ociskova M, Grambal A, Kamaradova D, et al. Are self-stigma, quality of life, and clinical data interrelated in schizophrenia spectrum patients? A cross-sectional outpatient study. Patient Prefer Adherence. 2016;10:265-74.
Holubova M, Prasko J, Ociskova M, Kantor K, Vanek J, Slepecky M, et al. Quality of life, self-stigma, and coping strategies in patients with neurotic spectrum disorders: a cross-sectional study. Psychol Res Behav Manag. 2019;12:81-95.
Oliveira SEH, Carvalho H, Esteves F. Internalized stigma and quality of life domains among people with mental illness: the mediating role of self-esteem. J Ment Health. 2016;25:55-61.
Daeppen JB, Faouzi M, Sanchez N, Rahhali N, Bineau S, Bertholet N. Quality of life depends on the drinking pattern in alcohol-dependent patients. Alcohol Alcohol. 2014;49:457-65.
Ortolá R, García-Esquinas E, Galán I, Rodríguez-Artalejo F. Patterns of alcohol consumption and health-related quality of life in older adults. Drug Alcohol Depend. 2016;159:166-73.
Leask CF, Sandlund M, Skelton DA, Altenburg TM, Cardon G, Chinapaw MJM, et al. Framework, principles and recommendations for utilising participatory methodologies in the co-creation and evaluation of public health interventions. Res Involv Engagem. 2019;5:2.